{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:30:45Z","timestamp":1793320245413,"version":"4.5.0"},"reference-count":174,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1038\/s41574-024-01016-5","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T07:06:55Z","timestamp":1721632015000},"page":"647-660","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Graves disease: latest understanding of pathogenesis and treatment options"],"prefix":"10.1038","volume":"20","author":[{"given":"Giulia","family":"Lanzolla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2100-3123","authenticated-orcid":false,"given":"Francesca","family":"Menconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"1016_CR1","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith, T. J. & Hegedus, L. Graves\u2019 disease. N. Engl. J. Med. 375, 1552\u20131565 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR2","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1136\/bmj.1.5441.1015","volume":"1","author":"DD Adams","year":"1965","unstructured":"Adams, D. D. Pathogenesis of the hyperthyroidism of Graves\u2019s disease. Br. Med. J. 1, 1015\u20131019 (1965).","journal-title":"Br. Med. J."},{"key":"1016_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jaut.2015.07.009","volume":"64","author":"HJ Lee","year":"2015","unstructured":"Lee, H. J., Li, C. W., Hammerstad, S. S., Stefan, M. & Tomer, Y. Immunogenetics of autoimmune thyroid diseases: a comprehensive review. J. Autoimmun. 64, 82\u201390 (2015).","journal-title":"J. Autoimmun."},{"key":"1016_CR4","first-page":"930","volume":"86","author":"TH Brix","year":"2001","unstructured":"Brix, T. H., Kyvik, K. O., Christensen, K. & Hegedus, L. Evidence for a major role of heredity in Graves\u2019 disease: a population-based study of two Danish twin cohorts. J. Clin. Endocrinol. Metab. 86, 930\u2013934 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR5","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1210\/jc.2005-1634","volume":"91","author":"MJ Simmonds","year":"2006","unstructured":"Simmonds, M. J. et al. Contribution of single nucleotide polymorphisms within FCRL3 and MAP3K7IP2 to the pathogenesis of Graves\u2019 disease. J. Clin. Endocrinol. Metab. 91, 1056\u20131061 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR6","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/s10875-012-9721-0","volume":"32","author":"N Inoue","year":"2012","unstructured":"Inoue, N. et al. Associations between autoimmune thyroid disease prognosis and functional polymorphisms of susceptibility genes, CTLA4, PTPN22, CD40, FCRL3, and ZFAT, previously revealed in genome-wide association studies. J. Clin. Immunol. 32, 1243\u20131252 (2012).","journal-title":"J. Clin. Immunol."},{"key":"1016_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12864-016-3276-z","volume":"17","author":"JJ Khong","year":"2016","unstructured":"Khong, J. J. et al. Pooled genome wide association detects association upstream of FCRL3 with Graves\u2019 disease. BMC Genomics 17, 939 (2016).","journal-title":"BMC Genomics"},{"key":"1016_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057758","volume":"8","author":"SX Zhao","year":"2013","unstructured":"Zhao, S. X. et al. A refined study of FCRL genes from a genome-wide association study for Graves\u2019 disease. PLoS One 8, e57758 (2013).","journal-title":"PLoS One"},{"key":"1016_CR9","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s12026-012-8302-x","volume":"54","author":"A Hasham","year":"2012","unstructured":"Hasham, A. & Tomer, Y. Genetic and epigenetic mechanisms in thyroid autoimmunity. Immunol. Res. 54, 204\u2013213 (2012).","journal-title":"Immunol. Res."},{"key":"1016_CR10","doi-asserted-by":"publisher","first-page":"691781","DOI":"10.3389\/fendo.2021.691781","volume":"12","author":"LC Faustino","year":"2021","unstructured":"Faustino, L. C. et al. Precision medicine in Graves\u2019 disease: CD40 gene variants predict clinical response to an anti-CD40 monoclonal antibody. Front. Endocrinol. 12, 691781 (2021).","journal-title":"Front. Endocrinol."},{"key":"1016_CR11","doi-asserted-by":"publisher","first-page":"dgz013","DOI":"10.1210\/clinem\/dgz013","volume":"105","author":"GJ Kahaly","year":"2020","unstructured":"Kahaly, G. J. et al. A novel anti-CD40 monoclonal antibody, iscalimab, for control of Graves hyperthyroidism-a proof-of-concept trial. J. Clin. Endocrinol. Metab. 105, dgz013 (2020).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s12020-020-02337-x","volume":"71","author":"NE Bufalo","year":"2021","unstructured":"Bufalo, N. E. et al. Polymorphisms of the genes CTLA4, PTPN22, CD40, and PPARG and their roles in Graves\u2019 disease: susceptibility and clinical features. Endocrine 71, 104\u2013112 (2021).","journal-title":"Endocrine"},{"key":"1016_CR13","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s40618-019-1010-9","volume":"42","author":"TT Shi","year":"2019","unstructured":"Shi, T. T. et al. Alterations in the intestinal microbiota of patients with severe and active Graves\u2019 orbitopathy: a cross-sectional study. J. Endocrinol. Invest. 42, 967\u2013978 (2019).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR14","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1210\/clinem\/dgad030","volume":"108","author":"F Biscarini","year":"2023","unstructured":"Biscarini, F. et al. Gut microbiome associated with graves disease and graves orbitopathy: the INDIGO multicenter European study. J. Clin. Endocrinol. Metab. 108, 2065\u20132077 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1089\/thy.2019.0036","volume":"29","author":"SHS Pearce","year":"2019","unstructured":"Pearce, S. H. S. et al. Antigen-specific immunotherapy with thyrotropin receptor peptides in Graves\u2019 hyperthyroidism: a phase I study. Thyroid 29, 1003\u20131011 (2019).","journal-title":"Thyroid"},{"key":"1016_CR16","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/cen.14296","volume":"93","author":"YH Chin","year":"2020","unstructured":"Chin, Y. H. et al. Prevalence of thyroid eye disease in Graves\u2019 disease: a meta-analysis and systematic review. Clin. Endocrinol. 93, 363\u2013374 (2020).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR17","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.beem.2011.10.001","volume":"26","author":"V Fatourechi","year":"2012","unstructured":"Fatourechi, V. Thyroid dermopathy and acropachy. Best Pract. Res. Clin. Endocrinol. Metab. 26, 553\u2013565 (2012).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"1016_CR18","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1055\/s-0035-1555762","volume":"47","author":"RS Bahn","year":"2015","unstructured":"Bahn, R. S. Current insights into the pathogenesis of Graves\u2019 ophthalmopathy. Horm. Metab. Res. 47, 773\u2013778 (2015).","journal-title":"Horm. Metab. Res."},{"key":"1016_CR19","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41572-020-0184-y","volume":"6","author":"TF Davies","year":"2020","unstructured":"Davies, T. F. et al. Graves\u2019 disease. Nat. Rev. Dis. Prim. 6, 52 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1016_CR20","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/S0889-8529(18)30486-9","volume":"16","author":"JP Kriss","year":"1987","unstructured":"Kriss, J. P. Pathogenesis and treatment of pretibial myxedema. Endocrinol. Metab. Clin. North Am. 16, 409\u2013415 (1987).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"1016_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00005792-199401000-00001","volume":"73","author":"V Fatourechi","year":"1994","unstructured":"Fatourechi, V., Pajouhi, M. & Fransway, A. F. Dermopathy of Graves disease (pretibial myxedema). Review of 150 cases. Medicine 73, 1\u20137 (1994).","journal-title":"Medicine"},{"key":"1016_CR22","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/archophthalmol.2011.29","volume":"129","author":"GB Bartley","year":"2011","unstructured":"Bartley, G. B. Rundle and his curve. Arch. Ophthalmol. 129, 356\u2013358 (2011).","journal-title":"Arch. Ophthalmol."},{"key":"1016_CR23","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","volume":"37","author":"L Bartalena","year":"2014","unstructured":"Bartalena, L. & Fatourechi, V. Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update. J. Endocrinol. Invest. 37, 691\u2013700 (2014).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/joim.13524","volume":"292","author":"L Bartalena","year":"2022","unstructured":"Bartalena, L. & Tanda, M. L. Current concepts regarding Graves\u2019 orbitopathy. J. Intern. Med. 292, 692\u2013716 (2022).","journal-title":"J. Intern. Med."},{"key":"1016_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","volume":"47","author":"MP Mourits","year":"1997","unstructured":"Mourits, M. P., Prummel, M. F., Wiersinga, W. M. & Koornneef, L. Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy. Clin. Endocrinol. 47, 9\u201314 (1997).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR26","doi-asserted-by":"publisher","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena, L. et al. The 2021 European Group on Graves\u2019 Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur. J. Endocrinol. 185, G43\u2013G67 (2021).","journal-title":"Eur. J. Endocrinol."},{"key":"1016_CR27","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/j.1365-2265.1995.tb02597.x","volume":"42","author":"P Perros","year":"1995","unstructured":"Perros, P., Crombie, A. L. & Kendall-Taylor, P. Natural history of thyroid associated ophthalmopathy. Clin. Endocrinol. 42, 45\u201350 (1995).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR28","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s12020-012-9703-2","volume":"42","author":"DS McLeod","year":"2012","unstructured":"McLeod, D. S. & Cooper, D. S. The incidence and prevalence of thyroid autoimmunity. Endocrine 42, 252\u2013265 (2012).","journal-title":"Endocrine"},{"key":"1016_CR29","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","volume":"14","author":"PN Taylor","year":"2018","unstructured":"Taylor, P. N. et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat. Rev. Endocrinol. 14, 301\u2013316 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1016_CR30","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1136\/bjo-2022-322442","volume":"108","author":"A Schuh","year":"2023","unstructured":"Schuh, A. et al. Presentation of Graves\u2019 orbitopathy within European Group On Graves\u2019 Orbitopathy (EUGOGO) centres from 2012 to 2019 (PREGO III). Br. J. Ophthalmol. 108, 294\u2013300 (2023).","journal-title":"Br. J. Ophthalmol."},{"key":"1016_CR31","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1210\/jc.2012-3873","volume":"98","author":"ML Tanda","year":"2013","unstructured":"Tanda, M. L. et al. Prevalence and natural history of Graves\u2019 orbitopathy in a large series of patients with newly diagnosed graves\u2019 hyperthyroidism seen at a single center. J. Clin. Endocrinol. Metab. 98, 1443\u20131449 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR32","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1146\/annurev-pathol-012513-104713","volume":"9","author":"Y Tomer","year":"2014","unstructured":"Tomer, Y. Mechanisms of autoimmune thyroid diseases: from genetics to epigenetics. Annu. Rev. Pathol. 9, 147\u2013156 (2014).","journal-title":"Annu. Rev. Pathol."},{"key":"1016_CR33","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaut.2015.09.006","volume":"67","author":"M Limbach","year":"2016","unstructured":"Limbach, M. et al. Epigenetic profiling in CD4+ and CD8+ T cells from Graves\u2019 disease patients reveals changes in genes associated with T cell receptor signaling. J. Autoimmun. 67, 46\u201356 (2016).","journal-title":"J. Autoimmun."},{"key":"1016_CR34","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fendo.2017.00086","volume":"8","author":"G Kleinau","year":"2017","unstructured":"Kleinau, G. et al. Structural-functional features of the thyrotropin receptor: a class A G-protein-coupled receptor at work. Front. Endocrinol. 8, 86 (2017).","journal-title":"Front. Endocrinol."},{"key":"1016_CR35","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.81415","volume":"11","author":"M Mezei","year":"2022","unstructured":"Mezei, M., Latif, R. & Davies, T. F. Computational model of the full-length TSH receptor. eLife 11, e81415 (2022).","journal-title":"eLife"},{"key":"1016_CR36","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/B978-0-12-381296-4.00022-1","volume":"485","author":"J Sanders","year":"2010","unstructured":"Sanders, J., Miguel, R. N., Furmaniak, J. & Smith, B. R. TSH receptor monoclonal antibodies with agonist, antagonist, and inverse agonist activities. Methods Enzymol. 485, 393\u2013420 (2010).","journal-title":"Methods Enzymol."},{"key":"1016_CR37","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3109\/08916939409010669","volume":"17","author":"JC Morris","year":"1994","unstructured":"Morris, J. C. et al. Identification of epitopes and affinity purification of thyroid stimulating auto-antibodies using synthetic human TSH receptor peptides. Autoimmunity 17, 287\u2013299 (1994).","journal-title":"Autoimmunity"},{"key":"1016_CR38","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1089\/thy.1997.7.867","volume":"7","author":"K Tahara","year":"1997","unstructured":"Tahara, K. et al. Epitopes for thyroid stimulating and blocking autoantibodies on the extracellular domain of the human thyrotropin receptor. Thyroid 7, 867\u2013877 (1997).","journal-title":"Thyroid"},{"key":"1016_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1172\/JCI114768","volume":"86","author":"AP Weetman","year":"1990","unstructured":"Weetman, A. P. et al. Thyroid-stimulating antibody activity between different immunoglobulin G subclasses. J. Clin. Invest. 86, 723\u2013727 (1990).","journal-title":"J. Clin. Invest."},{"key":"1016_CR40","first-page":"3346","volume":"81","author":"M Nakashima","year":"1996","unstructured":"Nakashima, M., Martin, A. & Davies, T. F. Intrathyroidal T cell accumulation in Graves\u2019 disease: delineation of mechanisms based on in situ T cell receptor analysis. J. Clin. Endocrinol. Metab. 81, 3346\u20133351 (1996).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR41","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1210\/en.2008-0878","volume":"150","author":"SA Morshed","year":"2009","unstructured":"Morshed, S. A., Latif, R. & Davies, T. F. Characterization of thyrotropin receptor antibody-induced signaling cascades. Endocrinology 150, 519\u2013529 (2009).","journal-title":"Endocrinology"},{"key":"1016_CR42","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1172\/JCI115297","volume":"88","author":"Y Nagayama","year":"1991","unstructured":"Nagayama, Y., Wadsworth, H. L., Russo, D., Chazenbalk, G. D. & Rapoport, B. Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin\/chorionic gonadotropin receptors. J. Clin. Invest. 88, 336\u2013340 (1991).","journal-title":"J. Clin. Invest."},{"key":"1016_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1172\/JCI0215745","volume":"110","author":"GD Chazenbalk","year":"2002","unstructured":"Chazenbalk, G. D. et al. Thyroid-stimulating autoantibodies in Graves disease preferentially recognize the free A subunit, not the thyrotropin holoreceptor. J. Clin. Invest. 110, 209\u2013217 (2002).","journal-title":"J. Clin. Invest."},{"key":"1016_CR44","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ecl.2009.01.006","volume":"38","author":"R Latif","year":"2009","unstructured":"Latif, R., Morshed, S. A., Zaidi, M. & Davies, T. F. The thyroid-stimulating hormone receptor: impact of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on multimerization, cleavage, and signaling. Endocrinol. Metab. Clin. North Am. 38, 319\u2013341 (2009).","journal-title":"Endocrinol. Metab. Clin. North Am."},{"key":"1016_CR45","doi-asserted-by":"publisher","first-page":"E871","DOI":"10.1210\/jc.2015-1528","volume":"100","author":"B Rapoport","year":"2015","unstructured":"Rapoport, B., Aliesky, H. A., Chen, C. R. & McLachlan, S. M. Evidence that TSH receptor a-subunit multimers, not monomers, drive antibody affinity maturation in Graves\u2019 disease. J. Clin. Endocrinol. Metab. 100, E871\u2013875 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR46","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1089\/thy.2012.0374","volume":"23","author":"SM McLachlan","year":"2013","unstructured":"McLachlan, S. M. & Rapoport, B. Thyrotropin-blocking autoantibodies and thyroid-stimulating autoantibodies: potential mechanisms involved in the pendulum swinging from hypothyroidism to hyperthyroidism or vice versa. Thyroid 23, 14\u201324 (2013).","journal-title":"Thyroid"},{"key":"1016_CR47","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1089\/thy.1993.3.315","volume":"3","author":"K Kasagi","year":"1993","unstructured":"Kasagi, K. et al. Fluctuating thyroid function depending on the balance between stimulating and blocking types of TSH receptor antibodies: a case report. Thyroid 3, 315\u2013318 (1993).","journal-title":"Thyroid"},{"key":"1016_CR48","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.4049\/jimmunol.0904135","volume":"186","author":"C Mao","year":"2011","unstructured":"Mao, C. et al. Impairment of regulatory capacity of CD4+CD25+ regulatory T cells mediated by dendritic cell polarization and hyperthyroidism in Graves\u2019 disease. J. Immunol. 186, 4734\u20134743 (2011).","journal-title":"J. Immunol."},{"key":"1016_CR49","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2265.2009.03544.x","volume":"71","author":"D Pan","year":"2009","unstructured":"Pan, D., Shin, Y. H., Gopalakrishnan, G., Hennessey, J. & De Groot, L. J. Regulatory T cells in Graves\u2019 disease. Clin. Endocrinol. 71, 587\u2013593 (2009).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR50","doi-asserted-by":"publisher","first-page":"a006957","DOI":"10.1101\/cshperspect.a006957","volume":"4","author":"Y Xing","year":"2012","unstructured":"Xing, Y. & Hogquist, K. A. T-cell tolerance: central and peripheral. Cold Spring Harb. Perspect. Biol. 4, a006957 (2012).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"1016_CR51","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1210\/jcem-69-6-1104","volume":"69","author":"A Martin","year":"1989","unstructured":"Martin, A., Schwartz, A. E., Friedman, E. W. & Davies, T. F. Successful production of intrathyroidal human T cell hybridomas: evidence for intact helper T cell function in Graves\u2019 disease. J. Clin. Endocrinol. Metab. 69, 1104\u20131108 (1989).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR52","doi-asserted-by":"publisher","first-page":"4060","DOI":"10.1210\/jc.2014-3011","volume":"99","author":"B Rapoport","year":"2014","unstructured":"Rapoport, B. & McLachlan, S. M. Graves\u2019 hyperthyroidism is antibody-mediated but is predominantly a Th1-type cytokine disease. J. Clin. Endocrinol. Metab. 99, 4060\u20134061 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR53","doi-asserted-by":"publisher","first-page":"eaay0524","DOI":"10.1126\/science.aay0524","volume":"367","author":"MA ElTanbouly","year":"2020","unstructured":"ElTanbouly, M. A. et al. VISTA is a checkpoint regulator for naive T cell quiescence and peripheral tolerance. Science 367, eaay0524 (2020).","journal-title":"Science"},{"key":"1016_CR54","doi-asserted-by":"publisher","first-page":"6320","DOI":"10.4049\/jimmunol.170.12.6320","volume":"170","author":"MP Armengol","year":"2003","unstructured":"Armengol, M. P. et al. Chemokines determine local lymphoneogenesis and a reduction of circulating CXCR4+ T and CCR7 B and T lymphocytes in thyroid autoimmune diseases. J. Immunol. 170, 6320\u20136328 (2003).","journal-title":"J. Immunol."},{"key":"1016_CR55","doi-asserted-by":"publisher","first-page":"7427","DOI":"10.1073\/pnas.1202064109","volume":"109","author":"R Fernando","year":"2012","unstructured":"Fernando, R. et al. Human fibrocytes coexpress thyroglobulin and thyrotropin receptor. Proc. Natl Acad. Sci. USA 109, 7427\u20137432 (2012).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1016_CR56","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0140-6736(93)91475-2","volume":"342","author":"A Feliciello","year":"1993","unstructured":"Feliciello, A. et al. Expression of thyrotropin-receptor mRNA in healthy and Graves\u2019 disease retro-orbital tissue. Lancet 342, 337\u2013338 (1993).","journal-title":"Lancet"},{"key":"1016_CR57","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s40618-019-01116-4","volume":"43","author":"YP Hai","year":"2020","unstructured":"Hai, Y. P., Lee, A. C. H., Frommer, L., Diana, T. & Kahaly, G. J. Immunohistochemical analysis of human orbital tissue in Graves\u2019 orbitopathy. J. Endocrinol. Invest. 43, 123\u2013137 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR58","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1530\/JME-11-0006","volume":"46","author":"S Kumar","year":"2011","unstructured":"Kumar, S., Nadeem, S., Stan, M. N., Coenen, M. & Bahn, R. S. A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves\u2019 ophthalmopathy. J. Mol. Endocrinol. 46, 155\u2013163 (2011).","journal-title":"J. Mol. Endocrinol."},{"key":"1016_CR59","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1089\/thy.2020.0088","volume":"31","author":"M Zhang","year":"2021","unstructured":"Zhang, M. et al. A promising mouse model of Graves\u2019 orbitopathy induced by adenovirus expressing thyrotropin receptor A subunit. Thyroid 31, 638\u2013648 (2021).","journal-title":"Thyroid"},{"key":"1016_CR60","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1210\/en.2014-1813","volume":"156","author":"HP Holthoff","year":"2015","unstructured":"Holthoff, H. P. et al. Prolonged TSH receptor A subunit immunization of female mice leads to a long-term model of Graves\u2019 disease, tachycardia, and cardiac hypertrophy. Endocrinology 156, 1577\u20131589 (2015).","journal-title":"Endocrinology"},{"key":"1016_CR61","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1210\/en.2013-1576","volume":"154","author":"S Moshkelgosha","year":"2013","unstructured":"Moshkelgosha, S., So, P. W., Deasy, N., Diaz-Cano, S. & Banga, J. P. Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves\u2019 orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 154, 3008\u20133015 (2013).","journal-title":"Endocrinology"},{"key":"1016_CR62","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1046\/j.1365-2265.2000.00959.x","volume":"52","author":"MN Gerding","year":"2000","unstructured":"Gerding, M. N. et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves\u2019 ophthalmopathy. Clin. Endocrinol. 52, 267\u2013271 (2000).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR63","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40618-020-01353-y","volume":"44","author":"F Nicoli","year":"2021","unstructured":"Nicoli, F. et al. Correlation between serum anti-TSH receptor autoantibodies (TRAbs) and the clinical feature of Graves\u2019 orbitopathy. J. Endocrinol. Invest. 44, 581\u2013585 (2021).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR64","doi-asserted-by":"publisher","first-page":"3464","DOI":"10.1210\/jc.2005-2813","volume":"91","author":"AK Eckstein","year":"2006","unstructured":"Eckstein, A. K. et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves\u2019 ophthalmopathy and help to predict severity and outcome of the disease. J. Clin. Endocrinol. Metab. 91, 3464\u20133470 (2006).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas, R. S. et al. Teprotumumab for the treatment of active thyroid eye disease. N. Engl. J. Med. 382, 341\u2013352 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR66","doi-asserted-by":"publisher","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard, J., Han, R., Horst, N., Cruikshank, W. W. & Smith, T. J. Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J. Immunol. 170, 6348\u20136354 (2003).","journal-title":"J. Immunol."},{"key":"1016_CR67","doi-asserted-by":"publisher","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","volume":"181","author":"RS Douglas","year":"2008","unstructured":"Douglas, R. S. et al. B cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J. Immunol. 181, 5768\u20135774 (2008).","journal-title":"J. Immunol."},{"key":"1016_CR68","doi-asserted-by":"publisher","first-page":"3281","DOI":"10.4049\/jimmunol.178.5.3281","volume":"178","author":"RS Douglas","year":"2007","unstructured":"Douglas, R. S., Gianoukakis, A. G., Kamat, S. & Smith, T. J. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves\u2019 disease may carry functional consequences for disease pathogenesis. J. Immunol. 178, 3281\u20133287 (2007).","journal-title":"J. Immunol."},{"key":"1016_CR69","doi-asserted-by":"publisher","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith, T. J. & Hoa, N. Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J. Clin. Endocrinol. Metab. 89, 5076\u20135080 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR70","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","volume":"181","author":"S Tsui","year":"2008","unstructured":"Tsui, S. et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease. J. Immunol. 181, 4397\u20134405 (2008).","journal-title":"J. Immunol."},{"key":"1016_CR71","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1210\/jc.2012-1771","volume":"98","author":"WB Minich","year":"2013","unstructured":"Minich, W. B. et al. Autoantibodies to the IGF1 receptor in Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 98, 752\u2013760 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR72","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1210\/jc.2012-2270","volume":"98","author":"AJ Varewijck","year":"2013","unstructured":"Varewijck, A. J. et al. Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves\u2019 ophthalmopathy. J. Clin. Endocrinol. Metab. 98, 769\u2013776 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR73","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1007\/s40618-020-01341-2","volume":"43","author":"G Lanzolla","year":"2020","unstructured":"Lanzolla, G. et al. Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves\u2019 disease: results of a pilot study. J. Endocrinol. Invest. 43, 1759\u20131768 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR74","first-page":"776","volume":"85","author":"JP Aniszewski","year":"2000","unstructured":"Aniszewski, J. P., Valyasevi, R. W. & Bahn, R. S. Relationship between disease duration and predominant orbital T cell subset in Graves\u2019 ophthalmopathy. J. Clin. Endocrinol. Metab. 85, 776\u2013780 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR75","doi-asserted-by":"publisher","first-page":"4273","DOI":"10.1210\/jc.2017-01349","volume":"102","author":"S Fang","year":"2017","unstructured":"Fang, S. et al. Regulation of orbital fibrosis and adipogenesis by pathogenic Th17 cells in graves orbitopathy. J. Clin. Endocrinol. Metab. 102, 4273\u20134283 (2017).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR76","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1167\/iovs.18-26268","volume":"60","author":"R Ma","year":"2019","unstructured":"Ma, R. et al. PH20 inhibits TGF\u03b21-induced differentiation of perimysial orbital fibroblasts via hyaluronan-CD44 pathway in thyroid-associated ophthalmopathy. Invest. Ophthalmol. Vis. Sci. 60, 1431\u20131441 (2019).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1016_CR77","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1001\/jamaophthalmol.2018.0806","volume":"136","author":"G Rotondo Dottore","year":"2018","unstructured":"Rotondo Dottore, G. et al. Association of T and B cells infiltrating orbital tissues with clinical features of Graves orbitopathy. JAMA Ophthalmol. 136, 613\u2013619 (2018).","journal-title":"JAMA Ophthalmol."},{"key":"1016_CR78","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn, R. S. Graves\u2019 ophthalmopathy. N. Engl. J. Med. 362, 726\u2013738 (2010).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR79","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1210\/clinem\/dgac645","volume":"108","author":"G Rotondo Dottore","year":"2023","unstructured":"Rotondo Dottore, G. et al. Insights into the role of DNA methylation and gene expression in Graves orbitopathy. J. Clin. Endocrinol. Metab. 108, e160\u2013e168 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR80","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1210\/jc.2017-02318","volume":"103","author":"R Martinez-Hernandez","year":"2018","unstructured":"Martinez-Hernandez, R. et al. A microRNA signature for evaluation of risk and severity of autoimmune thyroid diseases. J. Clin. Endocrinol. Metab. 103, 1139\u20131150 (2018).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR81","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.ncrna.2023.04.001","volume":"8","author":"K Shahraki","year":"2023","unstructured":"Shahraki, K. et al. Non-coding RNA-mediated epigenetic alterations in Grave\u2019s ophthalmopathy: a scoping systematic review. Noncoding RNA Res. 8, 426\u2013450 (2023).","journal-title":"Noncoding RNA Res."},{"key":"1016_CR82","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/bjophthalmol-2017-310723","volume":"102","author":"SY Jang","year":"2018","unstructured":"Jang, S. Y. et al. Role of microRNA-146a in regulation of fibrosis in orbital fibroblasts from patients with Graves\u2019 orbitopathy. Br. J. Ophthalmol. 102, 407\u2013414 (2018).","journal-title":"Br. J. Ophthalmol."},{"key":"1016_CR83","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","volume":"388","author":"S De Leo","year":"2016","unstructured":"De Leo, S., Lee, S. Y. & Braverman, L. E. Hyperthyroidism. Lancet 388, 906\u2013918 (2016).","journal-title":"Lancet"},{"key":"1016_CR84","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1210\/jc.2013-1954","volume":"98","author":"V Sundaresh","year":"2013","unstructured":"Sundaresh, V. et al. Comparative effectiveness of therapies for Graves\u2019 hyperthyroidism: a systematic review and network meta-analysis. J. Clin. Endocrinol. Metab. 98, 3671\u20133677 (2013).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR85","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJMra042972","volume":"352","author":"DS Cooper","year":"2005","unstructured":"Cooper, D. S. Antithyroid drugs. N. Engl. J. Med. 352, 905\u2013917 (2005).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR86","first-page":"CD003420","volume":"2010","author":"P Abraham","year":"2010","unstructured":"Abraham, P., Avenell, A., McGeoch, S. C., Clark, L. F. & Bevan, J. S. Antithyroid drug regimen for treating Graves\u2019 hyperthyroidism. Cochrane Database Syst. Rev. 2010, CD003420 (2010).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1016_CR87","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1530\/EJE-16-0725","volume":"176","author":"T Struja","year":"2017","unstructured":"Struja, T. et al. Can we predict relapse in Graves\u2019 disease? Results from a systematic review and meta-analysis. Eur. J. Endocrinol. 176, 87\u201397 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"1016_CR88","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1089\/thy.2016.0229","volume":"26","author":"DS Ross","year":"2016","unstructured":"Ross, D. S. et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343\u20131421 (2016).","journal-title":"Thyroid"},{"key":"1016_CR89","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1056\/NEJM198911163212001","volume":"321","author":"L Bartalena","year":"1989","unstructured":"Bartalena, L. et al. Use of corticosteroids to prevent progression of Graves\u2019 ophthalmopathy after radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 321, 1349\u20131352 (1989).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR90","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJMct1007101","volume":"364","author":"DS Ross","year":"2011","unstructured":"Ross, D. S. Radioiodine therapy for hyperthyroidism. N. Engl. J. Med. 364, 542\u2013550 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR91","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/cen.12688","volume":"84","author":"L Bartalena","year":"2016","unstructured":"Bartalena, L., Burch, H. B., Burman, K. D. & Kahaly, G. J. A 2013 European survey of clinical practice patterns in the management of Graves\u2019 disease. Clin. Endocrinol. 84, 115\u2013120 (2016).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR92","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1080\/17446651.2023.2167709","volume":"18","author":"A Ruslan","year":"2023","unstructured":"Ruslan, A. & Okosieme, O. E. Non-thionamide antithyroid drug options in Graves\u2019 hyperthyroidism. Expert Rev. Endocrinol. Metab. 18, 67\u201379 (2023).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"1016_CR93","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1210\/endrev\/bnaa022","volume":"41","author":"LC Lane","year":"2020","unstructured":"Lane, L. C., Cheetham, T. D., Perros, P. & Pearce, S. H. S. New therapeutic horizons for Graves\u2019 hyperthyroidism. Endocr. Rev. 41, 873\u2013884 (2020).","journal-title":"Endocr. Rev."},{"key":"1016_CR94","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.coi.2010.08.006","volume":"22","author":"CA Sabatos-Peyton","year":"2010","unstructured":"Sabatos-Peyton, C. A., Verhagen, J. & Wraith, D. C. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr. Opin. Immunol. 22, 609\u2013615 (2010).","journal-title":"Curr. Opin. Immunol."},{"key":"1016_CR95","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1038\/nm1226","volume":"11","author":"M Larche","year":"2005","unstructured":"Larche, M. & Wraith, D. C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 11, S69\u2013S76 (2005).","journal-title":"Nat. Med."},{"key":"1016_CR96","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1210\/en.2018-00306","volume":"159","author":"L Jansson","year":"2018","unstructured":"Jansson, L., Vrolix, K., Jahraus, A., Martin, K. F. & Wraith, D. C. Immunotherapy with apitopes blocks the immune response to TSH receptor in HLA-DR transgenic mice. Endocrinology 159, 3446\u20133457 (2018).","journal-title":"Endocrinology"},{"key":"1016_CR97","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/j.1365-2265.2010.03831.x","volume":"73","author":"M Evans","year":"2010","unstructured":"Evans, M. et al. Monoclonal autoantibodies to the TSH receptor, one with stimulating activity and one with blocking activity, obtained from the same blood sample. Clin. Endocrinol. 73, 404\u2013412 (2010).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR98","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s13317-012-0028-1","volume":"4","author":"J Furmaniak","year":"2013","unstructured":"Furmaniak, J., Sanders, J. & Rees Smith, B. Blocking type TSH receptor antibodies. Auto. Immun. Highlights 4, 11\u201326 (2013).","journal-title":"Auto. Immun. Highlights"},{"key":"1016_CR99","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1111\/cen.14681","volume":"96","author":"J Furmaniak","year":"2022","unstructured":"Furmaniak, J., Sanders, J., Sanders, P., Li, Y. & Rees Smith, B. TSH receptor specific monoclonal autoantibody K1-70(TM) targeting of the TSH receptor in subjects with Graves\u2019 disease and Graves\u2019 orbitopathy-results from a phase I clinical trial. Clin. Endocrinol. 96, 878\u2013887 (2022).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR100","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1210\/jc.2010-1935","volume":"96","author":"S Neumann","year":"2011","unstructured":"Neumann, S. et al. A new small-molecule antagonist inhibits Graves\u2019 disease antibody activation of the TSH receptor. J. Clin. Endocrinol. Metab. 96, 548\u2013554 (2011).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR101","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1210\/en.2013-1835","volume":"155","author":"S Neumann","year":"2014","unstructured":"Neumann, S. et al. A selective TSH receptor antagonist inhibits stimulation of thyroid function in female mice. Endocrinology 155, 310\u2013314 (2014).","journal-title":"Endocrinology"},{"key":"1016_CR102","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3389\/fendo.2016.00130","volume":"7","author":"R Latif","year":"2016","unstructured":"Latif, R., Realubit, R. B., Karan, C., Mezei, M. & Davies, T. F. TSH receptor signaling abrogation by a novel small molecule. Front. Endocrinol. 7, 130 (2016).","journal-title":"Front. Endocrinol."},{"key":"1016_CR103","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1089\/thy.2018.0349","volume":"29","author":"P Marcinkowski","year":"2019","unstructured":"Marcinkowski, P. et al. A new highly thyrotropin receptor-selective small-molecule antagonist with potential for the treatment of Graves\u2019 orbitopathy. Thyroid 29, 111\u2013123 (2019).","journal-title":"Thyroid"},{"key":"1016_CR104","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.smim.2009.05.008","volume":"21","author":"ME Munroe","year":"2009","unstructured":"Munroe, M. E. Functional roles for T cell CD40 in infection and autoimmune disease: the role of CD40 in lymphocyte homeostasis. Semin. Immunol. 21, 283\u2013288 (2009).","journal-title":"Semin. Immunol."},{"key":"1016_CR105","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/j.1365-2567.1997.00421.x","volume":"90","author":"G Carayanniotis","year":"1997","unstructured":"Carayanniotis, G., Masters, S. R. & Noelle, R. J. Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunology 90, 421\u2013426 (1997).","journal-title":"Immunology"},{"key":"1016_CR106","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.4049\/jimmunol.1200311","volume":"189","author":"AK Huber","year":"2012","unstructured":"Huber, A. K. et al. Genetically driven target tissue overexpression of CD40: a novel mechanism in autoimmune disease. J. Immunol. 189, 3043\u20133053 (2012).","journal-title":"J. Immunol."},{"key":"1016_CR107","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.cca.2016.09.004","volume":"462","author":"JD Lin","year":"2016","unstructured":"Lin, J. D. et al. Serum BAFF and thyroid autoantibodies in autoimmune thyroid disease. Clin. Chim. Acta 462, 96\u2013102 (2016).","journal-title":"Clin. Chim. Acta"},{"key":"1016_CR108","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1111\/cen.13872","volume":"90","author":"LC Lane","year":"2019","unstructured":"Lane, L. C. et al. Analysis of BAFF gene polymorphisms in UK Graves\u2019 disease patients. Clin. Endocrinol. 90, 170\u2013174 (2019).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR109","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/thy.2015.0029","volume":"25","author":"I Campi","year":"2015","unstructured":"Campi, I. et al. B cell activating factor (BAFF) and BAFF receptor expression in autoimmune and nonautoimmune thyroid diseases. Thyroid 25, 1043\u20131049 (2015).","journal-title":"Thyroid"},{"key":"1016_CR110","doi-asserted-by":"publisher","first-page":"4561","DOI":"10.1210\/en.2006-0507","volume":"147","author":"JA Gilbert","year":"2006","unstructured":"Gilbert, J. A. et al. Treatment of autoimmune hyperthyroidism in a murine model of Graves\u2019 disease with tumor necrosis factor-family ligand inhibitors suggests a key role for B cell activating factor in disease pathology. Endocrinology 147, 4561\u20134568 (2006).","journal-title":"Endocrinology"},{"issue":"Suppl. 1","key":"1016_CR111","doi-asserted-by":"publisher","first-page":"s2","DOI":"10.1191\/0961203305LU2109OA","volume":"14","author":"AC Allison","year":"2005","unstructured":"Allison, A. C. Mechanisms of action of mycophenolate mofetil. Lupus 14 (Suppl. 1), s2\u2013s8 (2005).","journal-title":"Lupus"},{"key":"1016_CR112","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","volume":"6","author":"GJ Kahaly","year":"2018","unstructured":"Kahaly, G. J. et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 6, 287\u2013298 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1016_CR113","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1056\/NEJMoa1012985","volume":"364","author":"C Marcocci","year":"2011","unstructured":"Marcocci, C. et al. Selenium and the course of mild Graves\u2019 orbitopathy. N. Engl. J. Med. 364, 1920\u20131931 (2011).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR114","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith, T. J. et al. Teprotumumab for thyroid-associated ophthalmopathy. N. Engl. J. Med. 376, 1748\u20131761 (2017).","journal-title":"N. Engl. J. Med."},{"key":"1016_CR115","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","volume":"9","author":"GJ Kahaly","year":"2021","unstructured":"Kahaly, G. J., Douglas, R. S., Holt, R. J., Sile, S. & Smith, T. J. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 9, 360\u2013372 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1016_CR116","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas, R. S. et al. Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 129, 438\u2013449 (2022).","journal-title":"Ophthalmology"},{"key":"1016_CR117","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1089\/thy.2022.0251","volume":"32","author":"HB Burch","year":"2022","unstructured":"Burch, H. B. et al. Management of thyroid eye disease: a consensus statement by the American Thyroid Association and the European Thyroid Association. Thyroid 32, 1439\u20131470 (2022).","journal-title":"Thyroid"},{"key":"1016_CR118","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1210\/clinem\/dgac627","volume":"108","author":"L Amarikwa","year":"2023","unstructured":"Amarikwa, L., Mohamed, A., Kim, S. H., Kossler, A. L. & Dosiou, C. Teprotumumab-related hyperglycemia. J. Clin. Endocrinol. Metab. 108, 858\u2013864 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR119","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1007\/s40618-022-01791-w","volume":"45","author":"L Bartalena","year":"2022","unstructured":"Bartalena, L., Marino, M., Marcocci, C. & Tanda, M. L. Teprotumumab for Graves\u2019 orbitopathy and ototoxicity: moving problems from eyes to ears? J. Endocrinol. Invest. 45, 1455\u20131457 (2022).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR120","doi-asserted-by":"publisher","first-page":"101069","DOI":"10.1016\/j.ajoc.2021.101069","volume":"22","author":"MB Safo","year":"2021","unstructured":"Safo, M. B. & Silkiss, R. Z. A case of ulcerative colitis associated with teprotumumab treatment for thyroid eye disease. Am. J. Ophthalmol. Case Rep. 22, 101069 (2021).","journal-title":"Am. J. Ophthalmol. Case Rep."},{"key":"1016_CR121","doi-asserted-by":"publisher","first-page":"e160","DOI":"10.1097\/IOP.0000000000001943","volume":"37","author":"DC Ashraf","year":"2021","unstructured":"Ashraf, D. C. et al. New-onset of inflammatory bowel disease in a patient treated with teprotumumab for thyroid associated ophthalmopathy. Ophthalmic Plast. Reconstr. Surg. 37, e160\u2013e164 (2021).","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"1016_CR122","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2021-242153","volume":"14","author":"TD Hoang","year":"2021","unstructured":"Hoang, T. D., Nguyen, N. T., Chou, E. & Shakir, M. K. Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease. BMJ Case Rep. 14, e242153 (2021).","journal-title":"BMJ Case Rep."},{"key":"1016_CR123","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/blood.V83.2.435.435","volume":"83","author":"ME Reff","year":"1994","unstructured":"Reff, M. E. et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83, 435\u2013445 (1994).","journal-title":"Blood"},{"key":"1016_CR124","doi-asserted-by":"publisher","first-page":"E1294","DOI":"10.1210\/jc.2013-3207","volume":"99","author":"AN McCoy","year":"2014","unstructured":"McCoy, A. N. et al. Rituximab (Rituxan) therapy for severe thyroid-associated ophthalmopathy diminishes IGF-1R+ T cells. J. Clin. Endocrinol. Metab. 99, E1294\u20131299 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR125","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1530\/eje.1.02325","volume":"156","author":"M Salvi","year":"2007","unstructured":"Salvi, M. et al. Treatment of Graves\u2019 disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur. J. Endocrinol. 156, 33\u201340 (2007).","journal-title":"Eur. J. Endocrinol."},{"key":"1016_CR126","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ophtha.2009.05.029","volume":"117","author":"D Khanna","year":"2010","unstructured":"Khanna, D. et al. Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 117, 133\u2013139.e2 (2010).","journal-title":"Ophthalmology"},{"key":"1016_CR127","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan, M. N. et al. Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 100, 432\u2013441 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR128","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi, M. et al. Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J. Clin. Endocrinol. Metab. 100, 422\u2013431 (2015).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR129","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1530\/EJE-16-0552","volume":"176","author":"MN Stan","year":"2017","unstructured":"Stan, M. N. & Salvi, M. MANAGEMENT OF ENDOCRINE DISEASE: rituximab therapy for Graves\u2019 orbitopathy \u2014 lessons from randomized control trials. Eur. J. Endocrinol. 176, R101\u2013R109 (2017).","journal-title":"Eur. J. Endocrinol."},{"key":"1016_CR130","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s42000-021-00282-6","volume":"20","author":"J Chen","year":"2021","unstructured":"Chen, J., Chen, G. & Sun, H. Intravenous rituximab therapy for active Graves\u2019 ophthalmopathy: a meta-analysis. Hormones 20, 279\u2013286 (2021).","journal-title":"Hormones"},{"key":"1016_CR131","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/thy.2020.0269","volume":"31","author":"G Vannucchi","year":"2021","unstructured":"Vannucchi, G. et al. Efficacy profile and safety of very low-dose rituximab in patients with Graves\u2019 orbitopathy. Thyroid 31, 821\u2013828 (2021).","journal-title":"Thyroid"},{"key":"1016_CR132","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1530\/EJE-08-0084","volume":"159","author":"KA Heemstra","year":"2008","unstructured":"Heemstra, K. A. et al. Rituximab in relapsing Graves\u2019 disease, a phase II study. Eur. J. Endocrinol. 159, 609\u2013615 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"1016_CR133","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1210\/jc.2006-2388","volume":"92","author":"D El Fassi","year":"2007","unstructured":"El Fassi, D., Nielsen, C. H., Bonnema, S. J., Hasselbalch, H. C. & Hegedus, L. B lymphocyte depletion with the monoclonal antibody rituximab in Graves\u2019 disease: a controlled pilot study. J. Clin. Endocrinol. Metab. 92, 1769\u20131772 (2007).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR134","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1210\/clinem\/dgab763","volume":"107","author":"TD Cheetham","year":"2022","unstructured":"Cheetham, T. D. et al. Adjuvant rituximab-exploratory trial in young people with Graves disease. J. Clin. Endocrinol. Metab. 107, 743\u2013754 (2022).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR135","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ajo.2018.07.038","volume":"195","author":"JV Perez-Moreiras","year":"2018","unstructured":"Perez-Moreiras, J. V. et al. Efficacy of tocilizumab in patients with moderate-to-severe corticosteroid-resistant Graves orbitopathy: a randomized clinical trial. Am. J. Ophthalmol. 195, 181\u2013190 (2018).","journal-title":"Am. J. Ophthalmol."},{"key":"1016_CR136","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40265-022-01726-y","volume":"82","author":"D Menon","year":"2022","unstructured":"Menon, D. & Bril, V. Pharmacotherapy of generalized myasthenia gravis with special emphasis on newer biologicals. Drugs 82, 865\u2013887 (2022).","journal-title":"Drugs"},{"key":"1016_CR137","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3390\/jcm10051004","volume":"10","author":"S Audia","year":"2021","unstructured":"Audia, S. & Bonnotte, B. Emerging therapies in immune thrombocytopenia. J. Clin. Med. 10, 1004 (2021).","journal-title":"J. Clin. Med."},{"key":"1016_CR138","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2023-000536","volume":"6","author":"M Benatar","year":"2024","unstructured":"Benatar, M., Wiendl, H., Nowak, R., Zheng, Y. & Macias, W. Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial. BMJ Neurol. Open 6, e000536 (2024).","journal-title":"BMJ Neurol. Open"},{"key":"1016_CR139","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ene.15561","volume":"30","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Batoclimab as an add-on therapy in neuromyelitis optica spectrum disorder patients with acute attacks. Eur. J. Neurol. 30, 195\u2013203 (2023).","journal-title":"Eur. J. Neurol."},{"key":"1016_CR140","doi-asserted-by":"publisher","first-page":"3122","DOI":"10.1210\/clinem\/dgad381","volume":"108","author":"GJ Kahaly","year":"2023","unstructured":"Kahaly, G. J. et al. Proof-of-concept and randomized, placebo-controlled trials of an fcrn inhibitor, batoclimab, for thyroid eye disease. J. Clin. Endocrinol. Metab. 108, 3122\u20133134 (2023).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR141","doi-asserted-by":"publisher","first-page":"1211473","DOI":"10.3389\/fendo.2023.1211473","volume":"14","author":"A Gulbins","year":"2023","unstructured":"Gulbins, A. et al. Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease. Front. Endocrinol. 14, 1211473 (2023).","journal-title":"Front. Endocrinol."},{"key":"1016_CR142","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1111\/bph.13693","volume":"174","author":"RF Place","year":"2017","unstructured":"Place, R. F., Krieger, C. C., Neumann, S. & Gershengorn, M. C. Inhibiting thyrotropin\/insulin-like growth factor 1 receptor crosstalk to treat Graves\u2019 ophthalmopathy: studies in orbital fibroblasts in vitro. Br. J. Pharmacol. 174, 328\u2013340 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"1016_CR143","doi-asserted-by":"publisher","first-page":"7S","DOI":"10.1016\/S0041-1345(03)00211-2","volume":"35","author":"SN Sehgal","year":"2003","unstructured":"Sehgal, S. N. Sirolimus: its discovery, biological properties, and mechanism of action. Transpl. Proc. 35, 7S\u201314S (2003).","journal-title":"Transpl. Proc."},{"key":"1016_CR144","doi-asserted-by":"publisher","first-page":"E1183","DOI":"10.1210\/jc.2013-4182","volume":"99","author":"L Zhang","year":"2014","unstructured":"Zhang, L. et al. Possible targets for nonimmunosuppressive therapy of Graves\u2019 orbitopathy. J. Clin. Endocrinol. Metab. 99, E1183\u20131190 (2014).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR145","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/IOP.0000000000001876","volume":"37","author":"JCP Roos","year":"2021","unstructured":"Roos, J. C. P., Eglitis, V. & Murthy, R. Inhibition of fibrotic contraction by sirolimus (Rapamycin) in an ex vivo model of thyroid eye disease. Ophthalmic Plast. Reconstr. Surg. 37, 366\u2013371 (2021).","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"1016_CR146","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1007\/s40618-022-01862-y","volume":"45","author":"G Lanzolla","year":"2022","unstructured":"Lanzolla, G. et al. Sirolimus as a second-line treatment for Graves\u2019 orbitopathy. J. Endocrinol. Invest. 45, 2171\u20132180 (2022).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR147","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamaophthalmol.2014.5103","volume":"133","author":"JD Stein","year":"2015","unstructured":"Stein, J. D. et al. Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease. JAMA Ophthalmol. 133, 290\u2013296 (2015).","journal-title":"JAMA Ophthalmol."},{"key":"1016_CR148","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1210\/clinem\/dgab070","volume":"106","author":"A Nilsson","year":"2021","unstructured":"Nilsson, A., Tsoumani, K. & Planck, T. Statins decrease the risk of orbitopathy in newly diagnosed patients with Graves disease. J. Clin. Endocrinol. Metab. 106, 1325\u20131332 (2021).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR149","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1089\/thy.2017.0430","volume":"28","author":"E Sabini","year":"2018","unstructured":"Sabini, E. et al. High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study. Thyroid 28, 386\u2013394 (2018).","journal-title":"Thyroid"},{"key":"1016_CR150","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1007\/s40618-018-0915-z","volume":"41","author":"G Lanzolla","year":"2018","unstructured":"Lanzolla, G. et al. Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study. J. Endocrinol. Invest. 41, 1417\u20131423 (2018).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR151","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S2213-8587(21)00238-2","volume":"9","author":"G Lanzolla","year":"2021","unstructured":"Lanzolla, G. et al. Statins for Graves\u2019 orbitopathy (STAGO): a phase 2, open-label, adaptive, single centre, randomised clinical trial. Lancet Diabetes Endocrinol. 9, 733\u2013742 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"1016_CR152","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/j.1365-2265.2011.04318.x","volume":"76","author":"TH Brix","year":"2012","unstructured":"Brix, T. H. & Hegedus, L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin. Endocrinol. 76, 457\u2013464 (2012).","journal-title":"Clin. Endocrinol."},{"key":"1016_CR153","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1089\/thy.2012.0007","volume":"22","author":"X Yin","year":"2012","unstructured":"Yin, X., Latif, R., Bahn, R. & Davies, T. F. Genetic profiling in Graves\u2019 disease: further evidence for lack of a distinct genetic contribution to Graves\u2019 ophthalmopathy. Thyroid 22, 730\u2013736 (2012).","journal-title":"Thyroid"},{"key":"1016_CR154","first-page":"4321","volume":"83","author":"Y Tomer","year":"1998","unstructured":"Tomer, Y., Barbesino, G., Greenberg, D. A., Concepcion, E. & Davies, T. F. Linkage analysis of candidate genes in autoimmune thyroid disease. III. Detailed analysis of chromosome 14 localizes Graves\u2019 disease-1 (GD-1) close to multinodular goiter-1 (MNG-1). International Consortium for the Genetics of Autoimmune Thyroid Disease. J. Clin. Endocrinol. Metab. 83, 4321\u20134327 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR155","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s40618-014-0228-9","volume":"38","author":"NE Bufalo","year":"2015","unstructured":"Bufalo, N. E. et al. TSHR intronic polymorphisms (rs179247 and rs12885526) and their role in the susceptibility of the Brazilian population to Graves\u2019 disease and Graves\u2019 ophthalmopathy. J. Endocrinol. Invest. 38, 555\u2013561 (2015).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR156","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3389\/fendo.2020.00392","volume":"11","author":"HN Li","year":"2020","unstructured":"Li, H. N., Li, X. R., Du, Y. Y., Yang, Z. F. & Lv, Z. T. The association between Foxp3 polymorphisms and risk of Graves\u2019 disease: a systematic review and meta-analysis of observational studies. Front. Endocrinol. 11, 392 (2020).","journal-title":"Front. Endocrinol."},{"key":"1016_CR157","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.gene.2018.06.023","volume":"672","author":"F Shehjar","year":"2018","unstructured":"Shehjar, F., Afroze, D., Misgar, R. A., Malik, S. A. & Laway, B. A. Association of FoxP3 promoter polymorphisms with the risk of Graves\u2019 disease in ethnic Kashmiri population. Gene 672, 88\u201392 (2018).","journal-title":"Gene"},{"key":"1016_CR158","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1515\/hsz-2018-0343","volume":"400","author":"D Zhang","year":"2019","unstructured":"Zhang, D. et al. MiR-23a-3p-regulated abnormal acetylation of FOXP3 induces regulatory T cell function defect in Graves\u2019 disease. Biol. Chem. 400, 639\u2013650 (2019).","journal-title":"Biol. Chem."},{"key":"1016_CR159","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nrendo.2013.56","volume":"9","author":"MJ Simmonds","year":"2013","unstructured":"Simmonds, M. J. GWAS in autoimmune thyroid disease: redefining our understanding of pathogenesis. Nat. Rev. Endocrinol. 9, 277\u2013287 (2013).","journal-title":"Nat. Rev. Endocrinol."},{"key":"1016_CR160","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.739707","volume":"11","author":"J Hou","year":"2021","unstructured":"Hou, J., Tang, Y., Chen, Y. & Chen, D. The role of the microbiota in Graves\u2019 disease and Graves\u2019 orbitopathy. Front. Cell Infect. Microbiol. 11, 739707 (2021).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"1016_CR161","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40618-020-01366-7","volume":"43","author":"M Mateu-Salat","year":"2020","unstructured":"Mateu-Salat, M., Urgell, E. & Chico, A. SARS-CoV-2 as a trigger for autoimmune disease: report of two cases of Graves\u2019 disease after COVID-19. J. Endocrinol. Invest. 43, 1527\u20131528 (2020).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR162","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1007\/s40618-021-01576-7","volume":"44","author":"G Lanzolla","year":"2021","unstructured":"Lanzolla, G., Marcocci, C. & Marino, M. Graves\u2019 disease and Graves\u2019 orbitopathy following COVID-19. J. Endocrinol. Invest. 44, 2011\u20132012 (2021).","journal-title":"J. Endocrinol. Invest."},{"key":"1016_CR163","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1210\/jc.2008-0095","volume":"93","author":"TF Davies","year":"2008","unstructured":"Davies, T. F. Infection and autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 93, 674\u2013676 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"1016_CR164","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1159\/000509615","volume":"9","author":"G Lanzolla","year":"2020","unstructured":"Lanzolla, G., Marcocci, C. & Marino, M. Oxidative stress in Graves disease and graves orbitopathy. Eur. Thyroid. J. 9, 40\u201350 (2020).","journal-title":"Eur. Thyroid. J."},{"key":"1016_CR165","doi-asserted-by":"publisher","first-page":"608428","DOI":"10.3389\/fendo.2020.608428","volume":"11","author":"G Lanzolla","year":"2020","unstructured":"Lanzolla, G., Marino, M. & Marcocci, C. Selenium in the treatment of Graves\u2019 hyperthyroidism and eye disease. Front. Endocrinol. 11, 608428 (2020).","journal-title":"Front. Endocrinol."},{"key":"1016_CR166","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1530\/EJE-18-0039","volume":"178","author":"W Wiersinga","year":"2018","unstructured":"Wiersinga, W. et al. Predictive score for the development or progression of Graves\u2019 orbitopathy in patients with newly diagnosed Graves\u2019 hyperthyroidism. Eur. J. Endocrinol. 178, 635\u2013643 (2018).","journal-title":"Eur. J. Endocrinol."},{"key":"1016_CR167","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.numecd.2015.01.003","volume":"25","author":"R Le Moli","year":"2015","unstructured":"Le Moli, R. et al. Type 2 diabetic patients with Graves\u2019 disease have more frequent and severe Graves\u2019 orbitopathy. Nutr. Metab. Cardiovasc. Dis. 25, 452\u2013457 (2015).","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"1016_CR168","doi-asserted-by":"publisher","first-page":"609895","DOI":"10.3389\/fendo.2020.609895","volume":"11","author":"A Naselli","year":"2020","unstructured":"Naselli, A. et al. Evidence that baseline levels of low-density lipoproteins cholesterol affect the clinical response of graves\u2019 ophthalmopathy to parenteral corticosteroids. Front. Endocrinol. 11, 609895 (2020).","journal-title":"Front. Endocrinol."},{"key":"1016_CR169","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1055\/s-0033-1343451","volume":"45","author":"B Wiesweg","year":"2013","unstructured":"Wiesweg, B., Johnson, K. T., Eckstein, A. K. & Berchner-Pfannschmidt, U. Current insights into animal models of Graves\u2019 disease and orbitopathy. Horm. Metab. Res. 45, 549\u2013555 (2013).","journal-title":"Horm. Metab. Res."},{"key":"1016_CR170","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.4049\/jimmunol.168.6.2789","volume":"168","author":"Y Nagayama","year":"2002","unstructured":"Nagayama, Y. et al. A novel murine model of Graves\u2019 hyperthyroidism with intramuscular injection of adenovirus expressing the thyrotropin receptor. J. Immunol. 168, 2789\u20132794 (2002).","journal-title":"J. Immunol."},{"key":"1016_CR171","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1172\/JCI7665","volume":"105","author":"S Costagliola","year":"2000","unstructured":"Costagliola, S. et al. Genetic immunization of outbred mice with thyrotropin receptor cDNA provides a model of Graves\u2019 disease. J. Clin. Invest. 105, 803\u2013811 (2000).","journal-title":"J. Clin. Invest."},{"key":"1016_CR172","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1089\/thy.2023.0299","volume":"33","author":"Y Bao","year":"2023","unstructured":"Bao, Y. et al. Cre-loxP system-based mouse model for investigating Graves\u2019 disease and associated orbitopathy. Thyroid 33, 1358\u20131367 (2023).","journal-title":"Thyroid"},{"key":"1016_CR173","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1089\/thy.2018.0326","volume":"29","author":"J Fassbender","year":"2019","unstructured":"Fassbender, J., Holthoff, H. P., Li, Z. & Ungerer, M. Therapeutic effects of short cyclic and combined epitope peptides in a long-term model of Graves\u2019 disease and orbitopathy. Thyroid 29, 258\u2013267 (2019).","journal-title":"Thyroid"},{"key":"1016_CR174","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1210\/en.2016-1845","volume":"158","author":"HP Holthoff","year":"2017","unstructured":"Holthoff, H. P. et al. Cyclic peptides for effective treatment in a long-term model of Graves disease and orbitopathy in female mice. Endocrinology 158, 2376\u20132390 (2017).","journal-title":"Endocrinology"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01016-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01016-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T09:05:03Z","timestamp":1728637503000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41574-024-01016-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":174,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["1016"],"URL":"https:\/\/doi.org\/10.1038\/s41574-024-01016-5","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"20 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.M. is a member of the Advisory Board of Horizon Pharma. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}